Tuesday, October 4, 2022

561.316.3330

Biotechnology News Magazine

Veracyte Announces New Data Reinforcing Percepta Nasal Swab Test’s Clinical Performance and Utility in Lung Cancer Risk Assessment

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Veracyte, Inc. today announced new data showing that its Percepta Nasal Swab test accurately assesses lung cancer risk among current and former smokers with lung nodules, regardless of their smoking history burden and whether they are considered high risk for lung cancer based on U.S. Preventive Services Task Force(USPSTF) screening criteria. The findings were presented today at the American Thoracic Society 2022 International Conference (ATS 2022), being held in San Francisco.

“Our analysis showed that the nasal genomic classifier performed similarly well in patients across the spectrum of tobacco-related risk,” said Carla R. Lamb, M.D., a pulmonary and critical care physician and Director of Interventional Pulmonary at Lahey Hospital & Medical Center who presented the study findings. “These findings suggest that the test can be reliably used in ever-smokers whose lung nodules were found incidentally, as well as through screening.”

For the study, researchers evaluated data from a subset of 291 current and former smokers with lung nodules who were part of the original clinical validation study for the Percepta Nasal Swab test. Among these individuals, 213 (73%) met USPSTF screening criteria (pack years ≥20, years since quit <15, age 50-80 years), while 78 (27%) did not. Researchers compared the performance of the classifier in the two patient subsets and found no statistically significant differences in the classifier’s sensitivity and specificity between the two groups.

Specifically, among those who met the USPSTF criteria for lung cancer screening, the test’s sensitivity was 96% when it identified a nodule as low risk for cancer and its specificity was 94% when it identified it as high risk. Among patients who did not meet the USPSTF lung cancer screening eligibility, the test’s sensitivity was 100% when it identified nodules as low risk for cancer and its specificity was 88% when it identified them as high risk.

“The data presented today reinforce the important role that the Percepta Nasal Swab classifier may play in helping to guide next steps for current and former smokers with lung nodules – including those who may be considered low risk based on their smoking history burden,” said Giulia C. Kennedy, Ph.D., Veracyte’s global chief scientific officer and chief medical officer. “More accurate, timely diagnosis of these patients could ultimately lead to fewer unnecessary diagnostic procedures among those without lung cancer, and timelier treatment for those with the disease.”

The Percepta Nasal Swab test’s performance in classifying lung cancer risk has previously been demonstrated, and it is being made available to a limited number of sites as the company develops the clinical utility evidence to support reimbursement.

Also at ATS 2022, Veracyte will host two Learning Theater events during which leading physicians will discuss their experiences incorporating novel genomic testing into the diagnoses of interstitial lung disease (ILD) and lung cancer, respectively:

Title: Integrating novel genomic data to improve ILD diagnostic and prognostic confidence
Presenter: Lisa H. Lancaster, M.D.
Date/Time: May 17, 12:30 p.m. PT
Location: Mini Theater #2

Title: Integrating the Percepta Genomic Sequencing Classifier for lung nodule risk stratification
Presenters: David Feller-Kopman, M.D. and Shaheen Islam, M.D.
Date/Time: May 17, 1:30 p.m. PT
Location: Mini Theater #1

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine